The second European interdisciplinary Ewing sarcoma research summit: A joint effort to deconstructing the multiple layers of a complex disease

Heinrich Kovar (Corresponding Author), James Amatruda, Erika Brunet, Stefan Burdach, Florencia Cidre-Aranaz, Enrique De Alava, Uta Dirksen, Wietske Van Der Ent, Patrick Grohar, Thomas G.P. Grünewald, Lee Helman, Peter Houghton, Kristiina Iljin, Eberhard Korsching, Marc Ladanyi, Elizabeth Lawlor, Stephen Lessnick, Joseph Ludwig, Paul Meltzer, Markus MetzlerJaume Mora, Richard Moriggl, Takuro Nakamura, Theodore Papamarkou, Branka Radic Sarikas, Francoise Rédini, Guenther H.S. Richter, Claudia Rossig, Keri Schadler, Beat W. Schäfer, Katia Scotlandi, Nathan C. Sheffield, Anang Shelat, Ewa Snaar-Jagalska, Poul Sorensen, Kimberly Stegmaier, Elizabeth Stewart, Alejandro Sweet-Cordero, Karoly Szuhai, Oscar M. Tirado, Franck Tirode, Jeffrey Toretsky, Kalliopi Tsafou, Aykut Üren, Andrei Zinovyev, Olivier Delattre

Research output: Contribution to journalArticleScientificpeer-review

19 Citations (Scopus)

Abstract

Despite multimodal treatment, long term outcome for patients with Ewing sarcoma is still poor. The second "European interdisciplinary Ewing sarcoma research summit" assembled a large group of scientific experts in the field to discuss their latest unpublished findings on the way to the identification of novel therapeutic targets and strategies. Ewing sarcoma is characterized by a quiet genome with presence of an EWSR1-ETS gene rearrangement as the only and defining genetic aberration. RNAsequencing of recently described Ewing-like sarcomas with variant translocations identified them as biologically distinct diseases. Various presentations adressed mechanisms of EWS-ETS fusion protein activities with a focus on EWS-FLI1. Data were presented shedding light on the molecular underpinnings of genetic permissiveness to this disease uncovering interaction of EWS-FLI1 with recently discovered susceptibility loci. Epigenetic context as a consequence of the interaction between the oncoprotein, cell type, developmental stage, and tissue microenvironment emerged as dominant theme in the discussion of the molecular pathogenesis and inter- and intratumor heterogeneity of Ewing sarcoma, and the difficulty to generate animal models faithfully recapitulating the human disease. The problem of preclinical development of biologically targeted therapeutics was discussed and promising perspectives were offered from the study of novel in vitro models. Finally, it was concluded that in order to facilitate rapid pre-clinical and clinical development of novel therapies in Ewing sarcoma, the community needs a platform to maintain knowledge of unpublished results, systems and models used in drug testing and to continue the open dialogue initiated at the first two Ewing sarcoma summits.

Original languageEnglish
Pages (from-to)8613-8624
Number of pages12
JournalOncotarget
Volume7
Issue number8
DOIs
Publication statusPublished - 1 Jan 2016
MoE publication typeA1 Journal article-refereed

Fingerprint

Ewing's Sarcoma
Research
Permissiveness
Combined Modality Therapy
Gene Rearrangement
Oncogene Proteins
Epigenomics
Molecular Biology
Therapeutics
Animal Models
Genome
Pharmaceutical Preparations

Keywords

  • Development
  • Epigenetics
  • Ewing sarcoma
  • Microenvironment
  • Therapy

Cite this

Kovar, H., Amatruda, J., Brunet, E., Burdach, S., Cidre-Aranaz, F., De Alava, E., ... Delattre, O. (2016). The second European interdisciplinary Ewing sarcoma research summit: A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget, 7(8), 8613-8624. https://doi.org/10.18632/oncotarget.6937
Kovar, Heinrich ; Amatruda, James ; Brunet, Erika ; Burdach, Stefan ; Cidre-Aranaz, Florencia ; De Alava, Enrique ; Dirksen, Uta ; Van Der Ent, Wietske ; Grohar, Patrick ; Grünewald, Thomas G.P. ; Helman, Lee ; Houghton, Peter ; Iljin, Kristiina ; Korsching, Eberhard ; Ladanyi, Marc ; Lawlor, Elizabeth ; Lessnick, Stephen ; Ludwig, Joseph ; Meltzer, Paul ; Metzler, Markus ; Mora, Jaume ; Moriggl, Richard ; Nakamura, Takuro ; Papamarkou, Theodore ; Sarikas, Branka Radic ; Rédini, Francoise ; Richter, Guenther H.S. ; Rossig, Claudia ; Schadler, Keri ; Schäfer, Beat W. ; Scotlandi, Katia ; Sheffield, Nathan C. ; Shelat, Anang ; Snaar-Jagalska, Ewa ; Sorensen, Poul ; Stegmaier, Kimberly ; Stewart, Elizabeth ; Sweet-Cordero, Alejandro ; Szuhai, Karoly ; Tirado, Oscar M. ; Tirode, Franck ; Toretsky, Jeffrey ; Tsafou, Kalliopi ; Üren, Aykut ; Zinovyev, Andrei ; Delattre, Olivier. / The second European interdisciplinary Ewing sarcoma research summit : A joint effort to deconstructing the multiple layers of a complex disease. In: Oncotarget. 2016 ; Vol. 7, No. 8. pp. 8613-8624.
@article{042c552812bf4e8bb6ce0ee5306c0aa5,
title = "The second European interdisciplinary Ewing sarcoma research summit: A joint effort to deconstructing the multiple layers of a complex disease",
abstract = "Despite multimodal treatment, long term outcome for patients with Ewing sarcoma is still poor. The second {"}European interdisciplinary Ewing sarcoma research summit{"} assembled a large group of scientific experts in the field to discuss their latest unpublished findings on the way to the identification of novel therapeutic targets and strategies. Ewing sarcoma is characterized by a quiet genome with presence of an EWSR1-ETS gene rearrangement as the only and defining genetic aberration. RNAsequencing of recently described Ewing-like sarcomas with variant translocations identified them as biologically distinct diseases. Various presentations adressed mechanisms of EWS-ETS fusion protein activities with a focus on EWS-FLI1. Data were presented shedding light on the molecular underpinnings of genetic permissiveness to this disease uncovering interaction of EWS-FLI1 with recently discovered susceptibility loci. Epigenetic context as a consequence of the interaction between the oncoprotein, cell type, developmental stage, and tissue microenvironment emerged as dominant theme in the discussion of the molecular pathogenesis and inter- and intratumor heterogeneity of Ewing sarcoma, and the difficulty to generate animal models faithfully recapitulating the human disease. The problem of preclinical development of biologically targeted therapeutics was discussed and promising perspectives were offered from the study of novel in vitro models. Finally, it was concluded that in order to facilitate rapid pre-clinical and clinical development of novel therapies in Ewing sarcoma, the community needs a platform to maintain knowledge of unpublished results, systems and models used in drug testing and to continue the open dialogue initiated at the first two Ewing sarcoma summits.",
keywords = "Development, Epigenetics, Ewing sarcoma, Microenvironment, Therapy",
author = "Heinrich Kovar and James Amatruda and Erika Brunet and Stefan Burdach and Florencia Cidre-Aranaz and {De Alava}, Enrique and Uta Dirksen and {Van Der Ent}, Wietske and Patrick Grohar and Gr{\"u}newald, {Thomas G.P.} and Lee Helman and Peter Houghton and Kristiina Iljin and Eberhard Korsching and Marc Ladanyi and Elizabeth Lawlor and Stephen Lessnick and Joseph Ludwig and Paul Meltzer and Markus Metzler and Jaume Mora and Richard Moriggl and Takuro Nakamura and Theodore Papamarkou and Sarikas, {Branka Radic} and Francoise R{\'e}dini and Richter, {Guenther H.S.} and Claudia Rossig and Keri Schadler and Sch{\"a}fer, {Beat W.} and Katia Scotlandi and Sheffield, {Nathan C.} and Anang Shelat and Ewa Snaar-Jagalska and Poul Sorensen and Kimberly Stegmaier and Elizabeth Stewart and Alejandro Sweet-Cordero and Karoly Szuhai and Tirado, {Oscar M.} and Franck Tirode and Jeffrey Toretsky and Kalliopi Tsafou and Aykut {\"U}ren and Andrei Zinovyev and Olivier Delattre",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.6937",
language = "English",
volume = "7",
pages = "8613--8624",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "8",

}

Kovar, H, Amatruda, J, Brunet, E, Burdach, S, Cidre-Aranaz, F, De Alava, E, Dirksen, U, Van Der Ent, W, Grohar, P, Grünewald, TGP, Helman, L, Houghton, P, Iljin, K, Korsching, E, Ladanyi, M, Lawlor, E, Lessnick, S, Ludwig, J, Meltzer, P, Metzler, M, Mora, J, Moriggl, R, Nakamura, T, Papamarkou, T, Sarikas, BR, Rédini, F, Richter, GHS, Rossig, C, Schadler, K, Schäfer, BW, Scotlandi, K, Sheffield, NC, Shelat, A, Snaar-Jagalska, E, Sorensen, P, Stegmaier, K, Stewart, E, Sweet-Cordero, A, Szuhai, K, Tirado, OM, Tirode, F, Toretsky, J, Tsafou, K, Üren, A, Zinovyev, A & Delattre, O 2016, 'The second European interdisciplinary Ewing sarcoma research summit: A joint effort to deconstructing the multiple layers of a complex disease', Oncotarget, vol. 7, no. 8, pp. 8613-8624. https://doi.org/10.18632/oncotarget.6937

The second European interdisciplinary Ewing sarcoma research summit : A joint effort to deconstructing the multiple layers of a complex disease. / Kovar, Heinrich (Corresponding Author); Amatruda, James; Brunet, Erika; Burdach, Stefan; Cidre-Aranaz, Florencia; De Alava, Enrique; Dirksen, Uta; Van Der Ent, Wietske; Grohar, Patrick; Grünewald, Thomas G.P.; Helman, Lee; Houghton, Peter; Iljin, Kristiina; Korsching, Eberhard; Ladanyi, Marc; Lawlor, Elizabeth; Lessnick, Stephen; Ludwig, Joseph; Meltzer, Paul; Metzler, Markus; Mora, Jaume; Moriggl, Richard; Nakamura, Takuro; Papamarkou, Theodore; Sarikas, Branka Radic; Rédini, Francoise; Richter, Guenther H.S.; Rossig, Claudia; Schadler, Keri; Schäfer, Beat W.; Scotlandi, Katia; Sheffield, Nathan C.; Shelat, Anang; Snaar-Jagalska, Ewa; Sorensen, Poul; Stegmaier, Kimberly; Stewart, Elizabeth; Sweet-Cordero, Alejandro; Szuhai, Karoly; Tirado, Oscar M.; Tirode, Franck; Toretsky, Jeffrey; Tsafou, Kalliopi; Üren, Aykut; Zinovyev, Andrei; Delattre, Olivier.

In: Oncotarget, Vol. 7, No. 8, 01.01.2016, p. 8613-8624.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - The second European interdisciplinary Ewing sarcoma research summit

T2 - A joint effort to deconstructing the multiple layers of a complex disease

AU - Kovar, Heinrich

AU - Amatruda, James

AU - Brunet, Erika

AU - Burdach, Stefan

AU - Cidre-Aranaz, Florencia

AU - De Alava, Enrique

AU - Dirksen, Uta

AU - Van Der Ent, Wietske

AU - Grohar, Patrick

AU - Grünewald, Thomas G.P.

AU - Helman, Lee

AU - Houghton, Peter

AU - Iljin, Kristiina

AU - Korsching, Eberhard

AU - Ladanyi, Marc

AU - Lawlor, Elizabeth

AU - Lessnick, Stephen

AU - Ludwig, Joseph

AU - Meltzer, Paul

AU - Metzler, Markus

AU - Mora, Jaume

AU - Moriggl, Richard

AU - Nakamura, Takuro

AU - Papamarkou, Theodore

AU - Sarikas, Branka Radic

AU - Rédini, Francoise

AU - Richter, Guenther H.S.

AU - Rossig, Claudia

AU - Schadler, Keri

AU - Schäfer, Beat W.

AU - Scotlandi, Katia

AU - Sheffield, Nathan C.

AU - Shelat, Anang

AU - Snaar-Jagalska, Ewa

AU - Sorensen, Poul

AU - Stegmaier, Kimberly

AU - Stewart, Elizabeth

AU - Sweet-Cordero, Alejandro

AU - Szuhai, Karoly

AU - Tirado, Oscar M.

AU - Tirode, Franck

AU - Toretsky, Jeffrey

AU - Tsafou, Kalliopi

AU - Üren, Aykut

AU - Zinovyev, Andrei

AU - Delattre, Olivier

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Despite multimodal treatment, long term outcome for patients with Ewing sarcoma is still poor. The second "European interdisciplinary Ewing sarcoma research summit" assembled a large group of scientific experts in the field to discuss their latest unpublished findings on the way to the identification of novel therapeutic targets and strategies. Ewing sarcoma is characterized by a quiet genome with presence of an EWSR1-ETS gene rearrangement as the only and defining genetic aberration. RNAsequencing of recently described Ewing-like sarcomas with variant translocations identified them as biologically distinct diseases. Various presentations adressed mechanisms of EWS-ETS fusion protein activities with a focus on EWS-FLI1. Data were presented shedding light on the molecular underpinnings of genetic permissiveness to this disease uncovering interaction of EWS-FLI1 with recently discovered susceptibility loci. Epigenetic context as a consequence of the interaction between the oncoprotein, cell type, developmental stage, and tissue microenvironment emerged as dominant theme in the discussion of the molecular pathogenesis and inter- and intratumor heterogeneity of Ewing sarcoma, and the difficulty to generate animal models faithfully recapitulating the human disease. The problem of preclinical development of biologically targeted therapeutics was discussed and promising perspectives were offered from the study of novel in vitro models. Finally, it was concluded that in order to facilitate rapid pre-clinical and clinical development of novel therapies in Ewing sarcoma, the community needs a platform to maintain knowledge of unpublished results, systems and models used in drug testing and to continue the open dialogue initiated at the first two Ewing sarcoma summits.

AB - Despite multimodal treatment, long term outcome for patients with Ewing sarcoma is still poor. The second "European interdisciplinary Ewing sarcoma research summit" assembled a large group of scientific experts in the field to discuss their latest unpublished findings on the way to the identification of novel therapeutic targets and strategies. Ewing sarcoma is characterized by a quiet genome with presence of an EWSR1-ETS gene rearrangement as the only and defining genetic aberration. RNAsequencing of recently described Ewing-like sarcomas with variant translocations identified them as biologically distinct diseases. Various presentations adressed mechanisms of EWS-ETS fusion protein activities with a focus on EWS-FLI1. Data were presented shedding light on the molecular underpinnings of genetic permissiveness to this disease uncovering interaction of EWS-FLI1 with recently discovered susceptibility loci. Epigenetic context as a consequence of the interaction between the oncoprotein, cell type, developmental stage, and tissue microenvironment emerged as dominant theme in the discussion of the molecular pathogenesis and inter- and intratumor heterogeneity of Ewing sarcoma, and the difficulty to generate animal models faithfully recapitulating the human disease. The problem of preclinical development of biologically targeted therapeutics was discussed and promising perspectives were offered from the study of novel in vitro models. Finally, it was concluded that in order to facilitate rapid pre-clinical and clinical development of novel therapies in Ewing sarcoma, the community needs a platform to maintain knowledge of unpublished results, systems and models used in drug testing and to continue the open dialogue initiated at the first two Ewing sarcoma summits.

KW - Development

KW - Epigenetics

KW - Ewing sarcoma

KW - Microenvironment

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84961626003&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6937

DO - 10.18632/oncotarget.6937

M3 - Article

C2 - 26802024

AN - SCOPUS:84961626003

VL - 7

SP - 8613

EP - 8624

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 8

ER -